# PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer

> **NCT02483884** · PHASE1,PHASE2 · TERMINATED · sponsor: **Life Molecular Imaging SA** · enrollment: 30 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** [68Ga]RM2
- **PROCEDURE:** PET/CT

## Key facts

- **NCT ID:** NCT02483884
- **Lead sponsor:** Life Molecular Imaging SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2017-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02483884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02483884, "PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02483884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*